Muromonab-CD3 and antithymocyte globulin in renal transplantation

Annals of Pharmacotherapy

Volumn 31, Issue 11, 1997, Pages 1370-1377

  Burk, Muriel L ^a   Matuszewski, Karl A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University HealthSystem Consortium   (United States)

Author keywords

Antithymocyte globulin; Immunosuppression; Muromonab CD3; Transplantation

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYCLOSPORIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; OKT 3; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; CHILL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; FEVER; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HOSPITAL CHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG EDEMA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030683988     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101115     Document Type: Review

References (38)

1. Tolkoff-Rubin NE. Dialysis and transplantation. Sci Am 1993;11:1-26.
2. American Hospital Formulary Services drug information 95. Atgam. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 1995:2599-605.
3. Atgam. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1993:448b-d.
4. Package insert. Atgam (anti-thymocyte globulin [equine] sterile solution). Kalamazoo, MI: Upjohn Company, 1995.
5. Muromonab-CD3. In: Drug information for the health care professional. 15th ed. Rockville, MD: United States Pharmacopeial Convention, Inc., 1995:1917.
6. Orthoclone. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1996:739-739e.
7. Package insert. Orthoclone OKT3 Sterile Solution (muromonab-CD3). Raritan, NJ: Ortho Biotech, Inc., 1995.
8. Krensky AM, Clayberger C. Transplantation immunology. Pediatr Clin North Am 1994;41:819-39.
9. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51:865-94.
10. Steinmuller DR, Hodge E, Boshkos C, Streem SB, Novick AC, Bailey D. Prophylaxis and treatment of post-renal transplant rejection. Clev Clin J Med 1991;58:125-30.
11. Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 1989;37:871-99.
12. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995;60:1220-4.
13. Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF III, Monaco A, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993;55:44-50.
14. Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 1989;14(suppl 2):14-8.
15. Norman DJ, Kimball JA, Bennett WM, Shihab F, Batiuk TD, Meyer MM, et al. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transpl Int 1994;7:356-61.
16. Parlevliet KJ, Berge RJM, Raasveld MHM, Surachno J, Wilmink JM, Schellekens PA. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transplant 1994;9:698-703.
17. Abramowicz D, Goldman M, Mat O, Estermans G, Crusiaux A, Vanherweghem JL, et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transpl Int 1994;7:258-63.
18. Vigeral P, Chkoff N, Chatenoud L, Campos H, Lacombe M, Droz D, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Transplantation 1986;41:730-3.
19. Abouna GM, Kumar MSA, Stephan R, Prior JE, Lyons P, Bulova SI, et al. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. Transplant Proc 1993;25:2241-2.
20. Bock HA, Gallati H, Zurcher RM, Bachofen M, Mihatsch MJ, Landmann J, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 1995;59:830-40.
21. Lloveras J, Puig JM, Oliveras A, Orfilia A, Comerma I, Aubia J, et al. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA. Transplant Proc 1992;24:43-4.
22. Abouna GM, Al-Abdullah IH, Kelly-Sullivan D, Kumar MSA, Loose J, Phillips K, et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995;59: 1564-8.
23. Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM. OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 1993;55:1023-9.
24. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985;313:337-42.
25. Deierhoi MH, Barber WH, Curtis JJ, Julian BA, Luke RG, Hudson S, et al. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 1988; 11:86-9.
26. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Stuart FP. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection. Am J Kidney Dis 1988;11:94-8.
27. Petrie JJB, Rigby RJ, Hawley CM, Suranyl MG, Whitby M, Wall D, et al. Effect of OKT3 in steroid-resistant renal transplant rejection. Transplantation 1995;59:347-52.
28. Rowe PA, Fan KS, Gardiner DS, Macpherson SG, Bradley JA, Rodger RS, et al. Long-term outcome of the use of OKT3 to treat steroid-resistant acute renal allograft rejection. Transpl Int 1994;7:278-83.
29. Norman DJ, Barry JM, Bennett WM, Leone M, Henell K, Funnell B, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 1988;11:90-3.
30. Blumke M, Kirste G, Wanner U, Wilms H. Single center randomized tri-al using ATG v OKT3 treatment in steroid-resistant rejection crises after kidney transplantation. Transplant Proc 1989;21:1747.
31. 1997 Drug topics red book. Medical Economics, 1997:168,433.
32. Schommer JC, Pleil AM, Pathak DS. Two approaches to comparing hospital charges between cadaveric renal transplant patients who received Orthoclone OKT3 sterile solution or Atgam sterile solution for induction therapy. Clin Ther 1995;17:749-69.
33. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years - early events affecting transplant success. Transplantation 1992;53:59-64.
34. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
35. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995;345: 1321-5.
36. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-32.
37. Filo RS, Smith J, Leapman SB. Reversal of acute renal allograft rejection with adjunctive ATG therapy. Transplant Proc 1981;13:482-90.
38. Nowygrod R, Appel G, Hardy MA. Use of ATG for reversal of acute allograft rejection. Transplant Proc 1981;13:469-72.